Envoy Medical, Inc. (COCHW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jul 27Jul 30Aug 4Aug 11Aug 17Aug 24Aug 28Sep 3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.8x

Market Cap

$774199.29

MomentumView details →

1D Return

−1.74%

YTD Return

+1.54%

RSI (14)

50.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.8x

Market Cap

$774199.29

RSI (14)

50.0

MomentumView details →

1D Return

−1.74%

YTD Return

+1.54%

ProfitabilityView details →

Gross Margin

−385.51%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−708.48%

ROA (TTM)

−97.71%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−6.76%

EPS YoY

+49.80%

FCF YoY

−40.36%

Revenue CAGR 3Y

+0.56%

EPS CAGR 3Y

+17.45%

EBITDA YoY

−13.60%

EarningsView details →

EPS (Actual)

−$0.07

EPS Surprise

12.50%

Beats (12Q)

3/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

13.81%

Rev Surprise

2.00%

Capital & dividendView details →

Debt/Equity

0.25x

Current Ratio

1.73x

Quick Ratio

1.61x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

207000.00

Net Income (TTM)

−23.40M

Op. CF (TTM)

−21.53M

Next earningsNov 18, 2026 →

Latest newsMore news →

Envoy Medical, Inc. appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026.9d ago

Envoy Medical reported financial results for the second quarter ended June 30, 2026, on August 10, 2026.25d ago

Similar companies

NanoVibronix, Inc.NAOV Venus Concept Inc.VERO Bone Biologics CorporationBBLG Tivic Health Systems, Inc.TIVC Holdco Nuvo Group D.G Ltd. Ordinary SharesNUVO Tenon Medical, Inc.TNON Find similar companies →

Latest newsMore news →

Envoy Medical, Inc. appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026.9d ago Envoy Medical reported financial results for the second quarter ended June 30, 2026, on August 10, 2026.25d ago Envoy Medical announced that all 56 patients in its pivotal clinical trial for the Acclaim cochlear implant have passed the three-month visit milestone.45d ago